慢性儿童免疫性血小板减少症差异表达基因的生物信息学分析

夏悦昕; 王霓; 张力; 宋文倩; 邵林楠; 戚凝; 于卫建

doi:10.13201/j.issn.1004-2806-b.2019.10.006

慢性儿童免疫性血小板减少症差异表达基因的生物信息学分析

- 大连市血液中心(辽宁大连, 116000)

详细信息

通讯作者: 于卫建,E-mail:yuweijiandl@163.com

中图分类号: R457.1

收稿日期: 2019-03-15

Identification of key genes and pathways associated with chronic pediatric ITP by bioinformatics analysis

- Dalian Blood Center, Dalian, 116000, China

More Information

Corresponding author: YU Weijian, E-mail: yuweijiandl@163.com

Received Date: 15 March 2019

摘要

摘要: 目的:探究慢性儿童免疫性血小板减少症(ITP)的关键基因和信号通路,为研究慢性ITP的潜在分子机制提供新的思路。方法:从GEO数据库获得mRNA表达芯片数据集GSE46922,利用GEO2R筛选出DEGs,并利用DAVID对DEGs进行GO功能富集分析和KEGG信号转导通路富集分析。随后,构建PPI蛋白互作网络,筛选核心靶标。结果:筛选出274个表达上调基因,主要参与细胞骨架组构,基于肌动蛋白丝的过程,肌动蛋白纤维组织等生物过程。筛选出496个表达下调基因,主要参与动作电位和肌肉收缩等过程。KEGG分析发现,上调基因主要参与HIF-1信号通路。下调基因主要涉及焦点黏附、Rap1信号通路、PI3K-Akt信号通路、神经信号传递通路、肌动蛋白细胞骨架调控等信号通路。获得11个核心靶标:VEGFA,CCND1,ESR1,MYH14,ERBB2,CDKN3,PVALB,CDC20,CHEK1,MTOR和CFTR。结论:本研究通过生物信息学分析获得慢性ITP的关键基因和信号通路,为研究慢性ITP的发病机制提供了新的思路。核心靶标基因可作为诊断和预后评估的生物标志物。
- 生物信息学分析 /
- 慢性儿童免疫性血小板减少症 /
- 差异表达基因 /
- 血管内皮生长因子A
Abstract: Objective:To identify critical genes and pathways in order to unravel the molecular mechanisms associated with chronic ITP.Method:The gene expression profile dataset(GSE46922)was downloaded from GEO database.The DEGs were identified by GEO2R.GO and KEGG pathway enrichment analyses were carried out using DAVID database.Furthermore,PPI network was constructed by STRING database.Result:Totally 274 up-regulated genes were identified,which were enriched in biological processes of cytoskeleton organization,actin filament-based process and actin filament organization.Additionally,496 down-regulated genes were identified,which demonstrated enrichment in biological processes including action potential,muscle contraction and behavior.Pathway analysis revealed that the up-regulated DEGs were particularly involved in HIF-1 signaling pathway,while the down-regulated DEGs were mainly involved in focal adhesion,Rap1 signaling pathway and PI3K-Akt signaling pathway.The top 11 hub genes of PPI network were VEGFA,CCND1,ESR1,MYH14,ERBB2,CDKN3,PVALB,CDC20,CHEK1,MTOR and CFTR.Conclusion:The present study identified the DEGs and pathways in chronic ITP by bioinformatics analysis,which might provide novel insights for unraveling pathogenesis of chronic ITP.The hub genes might serve as biomarkers for diagnosis and prognosis evaluation.
- bioinformatics analysis /
- chronic pediatric immune thrombocytopenia /
- differentially expressed genes /
- VEGFA

HTML全文

参考文献(27)

[1]	Glanz J,France E,Xu S,et al.A population-based,multisite cohort study of the predictors of chronic idiopathic thrombocytopenic purpura in children[J].Pediatrics,2008,121:506-512.
[2]	Rodeghiero F,Stasi R,Gernsheimer T,et al.Standardization of terminology,definitions and outcome criteria in immune thrombocytopenic purpura of adults and children:report from an international working group[J].Blood,2009,113:2386-2393.
[3]	Nugent DJ.Immune thrombocytopenic purpura of childhood[J].Hematology Am Soc Hematol Educ Program,2006:97-103.
[4]	Semple JW,Milev Y,Cosgrave D,et al.Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura:relationship to platelet phenotype and antiplatelet T-cell reactivity[J].Blood,1996,87:4245-4254.
[5]	Del Vecchio GC,Giordano P,Tesse R,et al.Clinical significance of serum cytokine levels and thrombopoietic markers in childhood idiopathic thrombocytopenic purpura[J].Blood Transfus,2012,10:194-199.
[6]	Zhang B,Lo C,Shen L,et al.The role of vanin-1 and oxidative stress-related pathways in distinguishing acute and chronic pediatric ITP[J].Blood,2011,117:4569-4579.
[7]	Kuang Z,Guo L,Li X.Identification of key genes and pathways associated with classical Hodgkin lymphoma by bioinformatics analysis[J].Mol Med Rep,2017,16:4685-4693.
[8]	Jernås M,Hou Y,Stromberg Celind F,et al.Differences in gene expression and cytokine levels between newly diagnosed and chronic pediatric ITP[J].Blood,2013,122:1789-1792.
[9]	Liu Z,Liang G,Tan L,et al.High-efficient Screening Method for Identification of Key Genes in Breast Cancer Through Microarray and Bioinformatics[J].Anticancer Res,2017,37:4329-4335.
[10]	Xu Z,Zhou Y,Cao Y,et al.Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis[J].Med Oncol,2016,33:130.
[11]	Liu J,Li H,Sun L,et al.Aberrantly methylated-differentially expressed genes and pathways in colorectal cancer[J].Cancer Cell Int,2017,17:75.
[12]	Liang B,Li C,Zhao J.Identification of key pathways and genes in colorectal cancer using bioinformatics analysis[J].Med Oncol,2016,33:111.
[13]	Kanehisa M,Goto S.KEGG:kyoto encyclopedia of genes and genomes[J].Nucleic Acids Res,2000,28:27-30.
[14]	Szklarczyk D,Franceschini A,Wyder S,et al.STRING v10:Protein-protein interaction networks,integrated over the tree of life[J].Nucleic Acids Res,2015,D447-D452.
[15]	Shannon P,Markiel A,Ozier O,et al.Cytoscape:A software environment for integrated models of biomolecular interaction networks[J].Genome Res,2003,2498-2504.
[16]	Liang B,Li C,Zhao J.Identification of key pathways and genes in colorectal cancer using bioinformatics analysis[J].Med Oncol,2016,111.
[17]	Clauss M,Gerlach M,Gerlach H,et al.Vascular permeability factor:a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity,and promotes monocyte migration[J].J Exp Med,1990,172:1535-1545.
[18]	Wartiovaara U,Salven P,Mikkola H,et al.Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation[J].Thromb Haemost,1998,80:171-175.
[19]	Baeriswyl V,Christofori G.The angiogenic switch in carcinogenesis[J].Semin Cancer Biol,2009,19:329-337.
[20]	Chen HX,Xu XX,Tan BZ,et al.MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma[J].Cell Physiol Biochem,2017,41:933-946.
[21]	Zhang RY,Liu YY,Qu HP,et al.The angiogenic factors and their soluble receptors in sepsis:friend,foe,or both?[J].Crit Care,2013,17:446.
[22]	Gerber HP,McMurtrey A,Kowalski J,et al.Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway.Requirement for Flk-1/KDR activation[J].J Biol Chem,1998,273:30336-30343.
[23]	Gerber HP,Condorelli F,Park J,et al.Differential transcriptional regulation of the two VEGF receptor genes.Flt-1,but not Flk-1/KDR,is up-regulated by hypoxia[J].J Biol Chem,1997,272:23659-23667.
[24]	Belair DG,Le NN,Murphy WL.Regulating VEGF signaling in platelet concentrates via specific VEGF sequestering[J].Biomater Sci,2016,4:819-825.
[25]	Mehta D,Malik AB.Regulating endothelial permeability[J].Physiol Rev,2006,86:279-367.
[26]	Mehta D.Focal adhesion kinase regulation of endothelial barrier function,apoptosis,and neovascularization[J].Microvasc Res,2012,83:1-2.
[27]	Naikoo NA,Dil-Afroze,Rasool R,et al.Upregulation of vascular endothelial growth factor (VEGF),its role in progression and prognosis of non-small cell lung carcinoma[J].Cancer Genet,2017,216:67-73.